Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name	Blinatumomab + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Vincristine Sulfate
Synonyms
Therapy Description

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 12 of 12 entries

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
Blinatumomab	Blincyto	anti-CD19/anti-CD3 recombinant bispecific\|monoclonal antibody MT103\|MEDI-538	CD19 Antibody 21	Blincyto (blinatumomab) is a bispecific antibody that binds both CD19 on B-cells and the CD3 complex on T-cells, therefore facilitates T-cell mediated killing of CD19-expressing tumor cells (PMID: 26337639). Blincyto (blinatumomab) is FDA-approved for use in adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL), CD19-positive B-cell precursor ALL in remission, and CD19-positive, BCR-ABL1-negative B-cell precursor ALL in the consolidation phase (FDA.gov).
Calaspargase pegol-mknl	Asparlas	CALASP\|EZN-2285EZN 2285\|EZN2285\|SC-PEG E. coli L-asparaginase		Asparlas (calaspargase pegol-mknl) is a pegylated version of L-asparaginase derived from E.coli, which converts L-asparagine to ammonia and L-aspartic acid, potentially resulting in reduced levels of asparagine leading to inhibition of protein synthesis and tumor cell proliferation, and increased cell death (NCI Drug Dictionary). Asparlas (calaspargase pegol-mknl) is approved as a component of multi-agent chemotherapy in acute lymphoblastic leukemia (FDA.gov).
Cyclophosphamide	Cytoxan	CPM	Chemotherapy - Alkylating 18	Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
Cytarabine	Cytosar-U	Ara-C		Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).
Dasatinib	Sprycel	BMS-354825	ABL Inhibitor (pan) 9 BCR-ABL Inhibitor 32 BTK inhibitor 38 CSF1R Inhibitor 28 DDR1 Inhibitor 10 DDR2 inhibitor 7 KIT Inhibitor 57 PDGFR Inhibitor (Pan) 30 SRC Inhibitor 31 TNK2 Inhibitor 7	Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).
Daunorubicin	Cerubidine	Rubidomycin\|daunomycin hydrochloride\|rubomycin C\|Acetyladriamycin	Chemotherapy - Anthracycline 13	Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov).
Dexamethasone	Adexone	Desametasone
Hydrocortisone		Cortisol
Inotuzumab ozogamicin	Besponsa	CMC-544\|InO	CD22 Immune Cell Therapy 15	Besponsa (inotuzumab ozogamicin) consists of calecheamicin covalently linked to anti-CD22 antibody, which delivers calecheamicin into CD22-positive cells, potentially leading to DNA damage and apoptosis (PMID: 24389139). Besponsa (inotuzumab ozogamicin) is FDA-approved for use in adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (FDA.gov).
Mercaptopurine	Purixan	6 MP\|Purinethol
Methotrexate	Abitrexate	Amethopterin	Chemotherapy - Antimetabolite 14	Methotrexate is an antimetabolite, which inhibits DHFR resulting in decreased immune function and antineoplastic activity and is FDA approved for psoriasis, RA, and several cancers including choriocarcinoma, AML, lung, head and neck and epidermoid (FDA.gov).
Vincristine Sulfate	Oncovin	22-Oxovincaleukoblastine\|vincristine		Oncovin (vincristine) binds microtubules and prevents mitotic spindle formation, resulting in cell-cycle arrest (NCI Drug Dictionary).

Showing 1 to 12 of 12 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 0 to 0 of 0 entries

Showing 0 to 0 of 0 entries

Filter rows:

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 1 of 1 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT06533748	Phase II	Blinatumomab + Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Methotrexate + Vincristine Sulfate Blinatumomab + Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Dasatinib + Daunorubicin + Dexamethasone + Hydrocortisone + Inotuzumab ozogamicin + Mercaptopurine + Methotrexate + Vincristine Sulfate Cytarabine + Dasatinib + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Thioguanine + Vincristine Sulfate	Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma	Recruiting	USA	0

Showing 1 to 1 of 1 entries

Filter rows:

Additional content available in CKB BOOST